Rescue
In Vitro Fertilization
In Vitro Maturation Techniques
Infertility
Oocytes
Journal
International journal of fertility & sterility
ISSN: 2008-076X
Titre abrégé: Int J Fertil Steril
Pays: Iran
ID NLM: 101487941
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
25
06
2019
accepted:
03
11
2019
entrez:
19
7
2020
pubmed:
19
7
2020
medline:
19
7
2020
Statut:
ppublish
Résumé
This study intends to present the role of rescue This was a retrospective case series study of five PCOS patients undergoing IVF treatment considered for cycle cancellation due to increased risk of ovarian hyperstimulation syndrome (OHSS) as group A or poor response to ovarian stimulation as group B. Patients in group A had high oestradiol levels and recruitment of high numbers of small/intermediate sized follicles that did not meet the criteria for human chorionic gonadotropin (hCG) triggering. Patients in group B responded inadequately to hormonal stimulation despite high gonadotropin dosage. Treatment was changed to rescue IVM cycles after the patients provided consent. In group A, three IVF patients deemed to have high chances of developing OHSS as evidenced by high oestradiol levels were converted to IVM. A total of the 58/68 oocytes retrieved were mature or matured Rescue IVM could be a viable option in PCOS patients undergoing IVF treatment who are unable to safely meet the criteria for hCG triggering due to overresponse to ovarian stimulation or ovarian resistance to high doses of stimulation. Conversion to IVM can still result in reasonable oocyte retrieval and lead to clinical pregnancy and live births without the risks of OHSS.
Sections du résumé
BACKGROUND
BACKGROUND
This study intends to present the role of rescue
MATERIALS AND METHODS
METHODS
This was a retrospective case series study of five PCOS patients undergoing IVF treatment considered for cycle cancellation due to increased risk of ovarian hyperstimulation syndrome (OHSS) as group A or poor response to ovarian stimulation as group B. Patients in group A had high oestradiol levels and recruitment of high numbers of small/intermediate sized follicles that did not meet the criteria for human chorionic gonadotropin (hCG) triggering. Patients in group B responded inadequately to hormonal stimulation despite high gonadotropin dosage. Treatment was changed to rescue IVM cycles after the patients provided consent.
RESULTS
RESULTS
In group A, three IVF patients deemed to have high chances of developing OHSS as evidenced by high oestradiol levels were converted to IVM. A total of the 58/68 oocytes retrieved were mature or matured
CONCLUSION
CONCLUSIONS
Rescue IVM could be a viable option in PCOS patients undergoing IVF treatment who are unable to safely meet the criteria for hCG triggering due to overresponse to ovarian stimulation or ovarian resistance to high doses of stimulation. Conversion to IVM can still result in reasonable oocyte retrieval and lead to clinical pregnancy and live births without the risks of OHSS.
Identifiants
pubmed: 32681626
doi: 10.22074/ijfs.2020.6025
pmc: PMC7382681
doi:
Types de publication
Journal Article
Langues
eng
Pagination
137-142Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
BMJ Case Rep. 2013 Oct 23;2013:
pubmed: 24155002
Adv Ther. 2018 Nov;35(11):1805-1815
pubmed: 30311070
Adv Ther. 2018 Jun;35(6):847-856
pubmed: 29869107
Arch Gynecol Obstet. 2018 Nov;298(5):1029-1035
pubmed: 30242498
Hum Reprod Update. 2002 Nov-Dec;8(6):559-77
pubmed: 12498425
Pathology. 1995 Oct;27(4):344-6
pubmed: 8771153
Clin Epidemiol. 2013 Dec 18;6:1-13
pubmed: 24379699
Hum Reprod. 2016 Sep;31(9):1997-2004
pubmed: 27343272
Fertil Steril. 2011 Mar 1;95(3):1137-40
pubmed: 21047635
Hum Reprod. 1992 Mar;7(3):320-7
pubmed: 1587936
Hum Reprod. 2003 Dec;18(12):2698-703
pubmed: 14645194
Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1129-31
pubmed: 27564226
Hum Fertil (Camb). 2006 Sep;9(3):175-80
pubmed: 17008270
Reprod Biomed Online. 2016 May;32(5):503-12
pubmed: 26968928
Br J Obstet Gynaecol. 1987 Nov;94(11):1098-102
pubmed: 3122819
Obstet Gynecol Int. 2015;2015:514159
pubmed: 26074966
Hum Reprod. 2011 Jul;26(7):1616-24
pubmed: 21505041
Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1527
pubmed: 27737594
Hum Reprod. 1999 Jul;14(7):1749-51
pubmed: 10402381
J Clin Endocrinol Metab. 1999 Jun;84(6):1897-9
pubmed: 10372683
Semin Reprod Med. 2010 Nov;28(6):513-8
pubmed: 21082511
Gynecol Endocrinol. 2016 Jun;32(6):431-8
pubmed: 26927948
J Obstet Gynaecol Can. 2014 Nov;36(11):1024-1033
pubmed: 25574681
Clin Exp Reprod Med. 2013 Mar;40(1):38-41
pubmed: 23614115
Hum Reprod. 1993 Feb;8(2):233-7
pubmed: 8473426
Avicenna J Med. 2015 Oct-Dec;5(4):123-7
pubmed: 26629467
Hum Reprod. 2006 Jun;21(6):1387-99
pubmed: 16449310
Am J Obstet Gynecol. 2019 Jun;220(6):575.e1-575.e11
pubmed: 30742828
N Engl J Med. 1999 Apr 29;340(17):1314-20
pubmed: 10219066
Facts Views Vis Obgyn. 2012;4(3):203-12
pubmed: 24753909
Fertil Steril. 2012 Aug;98(2):355-60
pubmed: 22658347
J Clin Endocrinol Metab. 2006 Mar;91(3):781-5
pubmed: 16418211
J Assist Reprod Genet. 1998 Jul;15(6):372-7
pubmed: 9673881
Gynecol Endocrinol. 2005 Jul;21(1):45-9
pubmed: 16048801
J Clin Endocrinol Metab. 2006 Mar;91(3):941-5
pubmed: 16368745
J Assist Reprod Genet. 2012 May;29(5):397-402
pubmed: 22382641
Eur J Obstet Gynecol Reprod Biol. 2010 Mar;149(1):68-71
pubmed: 20022685
Reprod Biol Endocrinol. 2018 Sep 17;16(1):90
pubmed: 30223902
Int J Fertil Steril. 2017 Apr-Jun;11(1):15-19
pubmed: 28367300